GlassScriptPhysician profile
Robert M Ehresman
NPI 1639335086
$1,177.97
in general payments reported to CMS, 2019-2025
20 companies · $83.41 in 2025
The $83.41 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $146 · 2020: $79.98 · 2021: $360 · 2022: $183 · 2023: $132 · 2024: $194 · 2025: $83.41.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $409.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $409.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $261.84 | 2019-2024 | Xarelto |
| Pfizer INC. | $223.77 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $145.09 | 2021-2024 | |
| Novo Nordisk INC | $116.33 | 2019-2024 | Ozempic, Rybelsus |
| Abbvie INC. | $92.69 | 2022-2025 | |
| Lilly USA, LLC | $54.39 | 2024-2025 | Mounjaro, Zepbound |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $47.19 | 2022-2025 | Caplyta |
| Amgen INC. | $30.65 | 2019-2024 | Repatha |
| Axsome Therapeutics, INC. | $29.60 | 2022 | |
| Gilead Sciences, INC. | $22.20 | 2023 | Epclusa |
| Lundbeck LLC | $22.10 | 2025 | Rexulti |
| Eisai INC. | $19.69 | 2024 | |
| Lexicon Pharmaceuticals, INC. | $17.31 | 2023 | Inpefa |
| Grifols USA, LLC | $16.15 | 2020 | |
| Glaxosmithkline, LLC. | $14.29 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.23 | 2019 | |
| Merck Sharp & Dohme LLC | $13.28 | 2023 | Vaxelis, M-M-R II, Gardasil 9 |
| Coopersurgical, INC. | $13.19 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.91 | 2022 | |
| Sanofi-Aventis U.S. LLC | $11.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Ehresman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.